Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Morningside Sets Up China Cancer JV with Can-Fite

publication date: Jan 20, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Morningside Asia Venture, the Hong Kong venture capital firm, signed a memorandum of understanding to establish a China joint venture with Can-Fite BioPharma, an Israeli company. Morningside will pay $7.5 million to Can-Fite for the China rights to CF102, a drug being developed to fight liver cancer. The money will underwrite all expenses of the JV through Phase II clinical trials. More details...

Stock Symbol: (TASE: CFBI)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners